Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
A Compendium of Insightful Information for Our Phoenix Community, Vol. 4 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.1, the newest version of our PK/PD software: What’s New in […]
Read MorePhoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]
Read MorePhoenix PK/PD Modeling and Simulation Software Certara’s Phoenix platform is the leading PK/PD modeling and simulation software used worldwide by 6,000 researchers at biopharmaceutical companies, academic institutions, and global regulatory agencies, including eleven divisions of the US FDA. Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with built-in, easy-to-use graphical user […]
Read MoreFocus on Patient Centricity In traditional drug development, limited engagement—or engagement too late in the development program—between sponsors, regulators, and payers can result in unacceptable delays of patient access to life-saving medicines. While alternative approaches such as Adaptive Licensing, which includes staggered approval, managed entry, and progressive authorization have expedited the process, it addresses only […]
Read MorePower Up Your Models with a Cloud-based Compute Grid Computationally-intensive PK/PD modeling and simulation applications, such as Phoenix® NLME™ and NONMEM®, require significant compute power to process models. Depending on the size and complexity of the job, models run on a local dual- or quad-core computer using serial computation can take 8 hours to days […]
Read MoreProduct Demo Schedule Accelerating Drug Discovery with D360 Date: Wednesday, July 19th, 2017 Time: 11:30 am to noon ET See how D360 allows you to make better use of data with spreadsheets for easy SAR or a form view to examine data for individual compounds Find out how D360 supports compound prioritization and design with SAR analysis […]
Read MoreA Compendium of Insightful Information for Our Phoenix Community June 2018 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.1, the newest version of our PK/PD software: What’s New […]
Read MoreQSP: Integrating Quantitative Drug Data with Knowledge of Its Mechanism of Action One of the biggest challenges—and, hence, the biggest opportunity for QSP—is drug attrition in Phase 2 clinical trials. Investigational medicines are usually tested for the first time in patients in Phase 2 clinical trials. This is the point when many drug programs fail. […]
Read MorePhoenix NLME: The Modern Population PK/PD Modeling Tool for Today’s Scientists Phoenix® NLMETM software is a population modeling and simulation solution for scientists with varying levels of experience—from the novice PK/PD scientists to the most advanced modelers. This comprehensive package includes integrated data preparation, modeling, and graphics tools with the same user interface that is used […]
Read MorePhoenix: The Most Comprehensive and Widely-used Software for Pharmacokinetic (PK), Pharmacodynamic (PD), and Toxicokinetic (TK) Modeling and Simulation Phoenix®, the industry’s premier PK/PD modeling and simulation software workbench, is used by over 6,000 scientists in 60 countries at nearly 2,000 institutions, including the top 50 global pharmaceutical companies, academic institutes, and research foundations. Regulatory agencies, including 11 divisions […]
Read More